Research library

Key finding

This comprehensive review synthesizes human trials in infectious disease, immune dysfunction and oncology and characterizes thymosin alpha-1 as a generally well-tolerated immune modulator.

Key finding

In a multicentre randomized severe-sepsis trial, thymosin alpha-1 added to conventional therapy was associated with improved clinical outcomes in the targeted patient population.

Key finding

In a double-blind pilot trial in severe acute pancreatitis, thymosin alpha-1 accelerated recovery of immune markers, reduced positive cultures and shortened intensive-care stay.

Key finding

This foundational paper isolated thymosin alpha-1, determined its amino-acid sequence and documented its immunological activity.

Key finding

In cell and mouse models of fungal infection, thymosin alpha-1 activated dendritic-cell Toll-like receptor signalling and strengthened protective Th1 immunity.

Key finding

The study reports that although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data.

Key finding

Thymalfasin (thymosin alpha-1; Talpha1) is a 28-amino acid polypeptide that has shown efficacy in the treatment of chronic hepatitis B virus (HBV) infection.

Key finding

To study the safety and efficacy of thymosin alpha1 in stimulating immune reconstitution in combination with highly active antiretroviral therapy (HAART), a phase II randomized, controlled open-label trial of subcutaneous thymosin alpha1 was undertaken for 12 weeks.

Key finding

Triple therapy with thymalfasin, PEG IFN alpha-2a, and ribavirin is an effective treatment option for difficult-to-treat HCV patients who are refractory to prior conventional treatment, with adequate tolerability.

Key finding

The study reports that after adjusting for confounding factors, Tα1 use was found to be significantly associated with a higher non-recovery rate than non-Tα1 use (OR 1.5, 95% CI 1.1-2.1, p = 0.028).

Key finding

Tα1 treatment significantly reduced mortality of severe COVID-19 patients.

Key finding

The results of this open label trial suggest that there may be a potential benefit to combining an immune modulator (T alpha 1) with an antiviral (IFN) in the treatment of chronic hepatitis C.

Key finding

INTRODUCTION: Sepsis is a life-threatening organ dysfunction caused by host immune response to infection.

Key finding

Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response.

Key finding

Treatment of chronic hepatitis B and C viruses (HBV and HCV) is still disappointing, and both are the major causes of liver cirrhosis and hepatocarcinoma.

Key finding

The hormone α1Thy could reduce, through the modulation of DCs, the amount of proinflammatory cytokines produced by T cells.

Key finding

These results suggest Talpha1 has activity in patients with metastatic melanoma and provide rationale for further clinical evaluation of this agent.

Key finding

The study reports that thymosin treatment was associated with significant improvements in relapse-free and overall survival, which was most pronounced for patients with nonbulky tumors.

Key finding

Thymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation.

Key finding

Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was first described and characterized from calf thymuses in 1977.